What we are studying
The purpose of this research study is to learn about the safety and tolerability of a new
investigational study drug, PF-06747143, and to find the best dose for treating AML. An
investigational drug is one that has not been approved by the U.S. Food and Drug
Administration (FDA) and is currently not approved for sale in the United States.
PF-06747143 is a humanized IgG1 monoclonal antibody. An antibody is a natural
protein made by our immune system that binds (or attachs) to other proteins and
molecules in the body to fight infection and its ill effects. The PF-06747143 antibody
selects and binds to a protein in your body which is called CXCR4.
Comprehensive Cancer Center of Wake Forest University will provide a parking voucher for all study related visits.